Journal
SEMINARS IN LIVER DISEASE
Volume 35, Issue 3, Pages 338-348Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0035-1562951
Keywords
nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; vitamin E; thiazolidinedione; obeticholic acid
Categories
Funding
- NIDDK NIH HHS [P30 DK097512] Funding Source: Medline
Ask authors/readers for more resources
Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available